Efficacy and Tolerability of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder in Adults

Santosh, Paramala J.; Sattar, Sanjida; Canagaratnam, Myooran
September 2011
CNS Drugs;2011, Vol. 25 Issue 9, p737
Academic Journal
This review examines the evidence regarding the efficacy and tolerability of long- and short-acting stimulant medications, as well as the non-stimulant medications atomoxetine and bupropion in the treatment of adult attention-deficit hyperactivity disorder (ADHD). Effect sizes in adults appear to be of almost the same magnitude as in school-age children when robust doses are used. There are adequate data demonstrating short-term efficacy and safety of medication in ADHD during adulthood but long-term studies are lacking, particularly in view of concerns regarding cardiovascular adverse events. There is some evidence that stimulant medication can improve driving per- formance in adults with ADHD. The extent to which medication may im- prove academic, occupational and social functioning in adults with ADHD is unclear, and future research should investigate these outcomes. Medication treatment of adults with ADHD in sports is controversial. Both stimulant and non-stimulant medications seem to be well tolerated. Monitoring of pulse and blood pressure is recommended with these drugs because of their cardiovascular effects. There have been extremely rare case reports of sudden death in adults and children treated with stimulants and atomoxetine, but it is difficult to clearly establish causality. In view of reports of treatment-related suicide-related behaviour with atomoxetine, it is recommended that adults should be observed for agitation, irritability, suicidal thinking, self-harming or unusual behaviour, particularly in the first months of treatment, or after a change of dose. ADHD in adults continues to remain an under-recognized disorder in many parts of the world and there is a lack of specialist clinics for assessment and treatment of adult ADHD. Studies to date have failed to show efficacy of medications in the treatment of ADHD in the substance misuse population. There is little evidence so far to suggest an increased misuse of stimulants or diversion amongst substance misusers; however, data are insufficient to draw firm conclusions. Further work is necessary to evaluate effective treatments in subgroups such as the substance misuse population, those with multiple comorbidities and different ADHD subtypes.


Related Articles

  • Identifying and treating adults with ADHD. Higgins, Edmund S.; D'Epiro, Peter // Patient Care;Jul2004, Vol. 38 Issue 7, p15 

    Explains why a psychiatrist prefers to treat attention-deficit/hyperactivity disorder (ADHD) patients with nonstimulant drug therapy. Findings of a research into the neuroscience of ADHD; Essential feature of ADHD in adults; Reason the prevalence of ADHD in adults is more controversial.

  • Methylphenidate.  // Reactions Weekly;3/22/2008, Issue 1194/1195, p24 

    The article describes the case of a 22-year-old woman with attention deficit hyperactivity disorder who developed pseudolymphoma during treatment with methylphenidate. The patient experienced recurrent, mildly pruritic crops of painless lesions that were mostly localised to her proximal upper...

  • Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Mészáros, Ágnes; Czobor, Pál; Bálint, Sára; Komlósi, Sarolta; Simon, Viktória; Bitter, István // International Journal of Neuropsychopharmacology;Sep2009, Vol. 12 Issue 8, p1137 

    Our objective was to conduct a meta-analysis of therapeutic efficacy of pharmacological treatment of adult ADHD based on data from controlled clinical trials. We used the search engines PubMed and Medline to identify relevant clinical trials. Short-term studies with double-blind parallel-group...

  • Atomoxetine.  // Reactions Weekly;9/13/2008, Issue 1219, p9 

    The article presents a case study of a 24-year-old man with attention-deficit hyperactivity disorder (ADHD) who developed haemospermia during treatment with atomoxetine. After receiving atomoxetine for several weeks, the patient developed haemospermia. The drug was stopped after 6 weeks of...

  • Methylphenidate interaction.  // Reactions Weekly;12/8/2007, Issue 1181, p25 

    The article describes the case of a 33-year-old man who is an alcoholic and has attention deficit hyperactivity disorder. The patient is taking disulfiram for his alcohol abuse when he got treated with methylphenidate. The two drugs interacted which made him experience a psychotic episode. He...

  • Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate: A Chart Review of Spanish Adults with Attention-Deficit Hyperactivity Disorder. Ramos-Quiroga, Josep Antoni; Bosch, Rosa; Castells, Xavier; Valero, Sergi; Nogueira, Mariana; Gómez, Nuria; Yelmo, Silvia; Ferrer, Marc; Martínez, Yolanda; Casas, Miguel // CNS Drugs;2008, Vol. 22 Issue 7, p603 

    BACKGROUND: The potential advantages of osmotic-release oral system (OROS) methylphenidate (Concerta) over immediate-release (IR) methylphenidate (Rubifen) in adults with attention-deficit hyperactivity disorder (ADHD), with respect to medication adherence, effectiveness and tolerability, are...

  • Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Mattingly, Greg W.; Weisler, Richard H.; Young, Joel; Adeyi, Ben; Dirks, Bryan; Babcock, Thomas; Lasser, Robert; Scheckner, Brian; Goodman, David W. // BMC Psychiatry;2013, Vol. 13 Issue 1, p1 

    Background: Despite the overall high degree of response to pharmacotherapy, consensus is lacking on how to judge clinical response or define optimal treatment/remission when treating adults with attention-deficit/ hyperactivity disorder (ADHD). This study examined clinical response and...

  • PHARMACOTHERAPY OF ADHD IN ADULTS. Wilens, Timothy E. // CNS Spectrums: The International Journal of Neuropsychiatric Med;May2008 Supplement 8, Vol. 13 Issue 5, p11 

    The article offers information on various pharmacotherapy options for adult attention-deficit/peractivity disorder (ADHD). It mentions several stimulants including Dexmethylphenidate, Methylphenidate and Amphetamine compounds and the nonstimulant Atomoxetine. They include antidepressants such as...

  • Optimal management of ADHD in older adults. Torgersen, Terje; Gjervan, Bjorn; Lensing, Michael B.; Rasmussen, Kirsten // Neuropsychiatric Disease & Treatment;Jan2016, Vol. 9, p79 

    Background: The manifestation of attention-deficit/hyperactivity disorder (ADHD) among older adults has become an interesting topic of interest due to an increasing number of adults aged 50 years and older (⩾50 years) seeking assessment for ADHD. Unfortunately, there is a lack of research...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics